Beth Israel Deaconess Medical Center-ko ikertzaileekin lankidetzan egindako argitalpenak (50)

2023

  1. Bleeding and Ischemic Risks of Ticagrelor Monotherapy After Coronary Interventions

    Journal of the American College of Cardiology, Vol. 82, Núm. 8, pp. 687-700

2022

  1. Copy number variants as modifiers of breast cancer risk for BRCA1/BRCA2 pathogenic variant carriers

    Communications biology, Vol. 5, Núm. 1, pp. 1061

  2. Erratum: Correction: Polygenic risk modeling for prediction of epithelial ovarian cancer risk (European journal of human genetics : EJHG (2022) 30 3 (349-362))

    European journal of human genetics : EJHG

  3. ISARIC-COVID-19 dataset: A Prospective, Standardized, Global Dataset of Patients Hospitalized with COVID-19

    Scientific Data, Vol. 9, Núm. 1

  4. Polygenic risk modeling for prediction of epithelial ovarian cancer risk

    European journal of human genetics : EJHG, Vol. 30, Núm. 3, pp. 349-362

  5. Ticagrelor Monotherapy After PCI in High-Risk Patients With Prior MI: A Prespecified TWILIGHT Substudy

    JACC: Cardiovascular Interventions, Vol. 15, Núm. 3, pp. 282-293

  6. Ticagrelor with and without aspirin in patients with a prior coronary artery bypass graft undergoing percutaneous coronary intervention: the TWILIGHT-CABG study

    EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, Vol. 18, Núm. 11, pp. e897-e909

2021

  1. A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers

    Nature Communications, Vol. 12, Núm. 1

  2. Erratum: Author Correction: A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers (Nature communications (2021) 12 1 (1078))

    Nature communications

  3. Impact of Age on the Safety and Efficacy of Ticagrelor Monotherapy in Patients Undergoing PCI

    JACC: Cardiovascular Interventions, Vol. 14, Núm. 13, pp. 1434-1446

  4. Motixafortide and pembrolizumab combined to nanoliposomal irinotecan, fluorouracil, and folinic acid in metastatic pancreatic cancer: The COMBAT/ KEYNOTE-202 trial

    Clinical Cancer Research, Vol. 27, Núm. 18, pp. 5020-5027

  5. Recurrence of iga nephropathy after kidney transplantation in adults

    Clinical Journal of the American Society of Nephrology, Vol. 16, Núm. 8, pp. 1247-1255

  6. Sex Differences among Patients with High Risk Receiving Ticagrelor with or without Aspirin after Percutaneous Coronary Intervention: A Subgroup Analysis of the TWILIGHT Randomized Clinical Trial

    JAMA Cardiology, Vol. 6, Núm. 9, pp. 1032-1041

  7. The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group

    npj Breast Cancer, Vol. 7, Núm. 1

  8. Ticagrelor Monotherapy Versus Dual-Antiplatelet Therapy After PCI: An Individual Patient-Level Meta-Analysis

    JACC: Cardiovascular Interventions, Vol. 14, Núm. 4, pp. 444-456

  9. Ticagrelor monotherapy in patients with chronic kidney disease undergoing percutaneous coronary intervention: TWILIGHT-CKD

    European Heart Journal, Vol. 42, Núm. 45, pp. 4683-4693

2020

  1. Association of genomic domains in BRCA1 and BRCA2 with prostate cancer risk and aggressiveness

    Cancer Research, Vol. 80, Núm. 3, pp. 624-638

  2. BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial

    Nature Medicine, Vol. 26, Núm. 6, pp. 878-885

  3. Characterization of the Cancer Spectrum in Men with Germline BRCA1 and BRCA2 Pathogenic Variants: Results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA)

    JAMA Oncology, Vol. 6, Núm. 8, pp. 1218-1230

  4. Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes

    Nature Genetics, Vol. 52, Núm. 1, pp. 56-73